INCHEON--(뉴스와이어)--CellFiber will jointly host the Next-Generation Stem Cell Manufacturing and Commercialization Strategy Workshop with Cytiva on Wednesday, 15 July 2026 at the Cytiva APAC Fast Trak™ Center in Songdo, Incheon. The hands-on program is designed for researchers and developers advancing mesenchymal stem cell (MSC) and induced pluripotent stem cell (iPSC) therapies from research into manufacturing and commercialization.

As MSC therapy development moves beyond research results toward real-world production, the shift to scalable, GMP-ready manufacturing has become decisive. Bringing together Cytiva’s bioprocessing expertise and CellFiber’s 3D cell culture technology, experts from both companies will work alongside participants to address the practical questions teams face in that transition — from commercialization roadmaps and research-to-manufacturing scale-up to the core GMP and process issues that determine commercial readiness.

A central feature is a hands-on session in which participants experience the integrated Cytiva - CellFiber workflow directly, complemented by Expert Clinic and Strategic Roundtable sessions on adherent stem cell scale-up and GMP process execution. The agenda spans both MSC and iPSC, giving teams weighing their next manufacturing step an applied, field-ready perspective rather than a product overview.

Program highlights (10:00-15:40)

· Commercialization roadmap for next-generation MSC therapies: from discovery to global commercialization

· Scale-up strategy for 3D MSC and iPSC manufacturing with CellFiber

· Expert Clinic: scale-up strategy and manufacturing execution for adherent stem cells

· Hands-on session: the integrated Cytiva-CellFiber workflow

· Strategic Roundtable: focused Q&A on core GMP process issues

Speakers include Mandy French, Chief Strategy Officer, CellFiber; Jeeheon Kang, Cell Therapy Field Application Specialist Leader, Cytiva; Kevin Tran, Senior Sales Specialist, CellFiber; and application and process development scientists from both organizations leading the hands-on session.

“Bringing a cell therapy program from the lab to the clinic depends on making the right manufacturing decisions early. This workshop gives teams a chance to work through those decisions hands-on, with an integrated workflow they can apply directly to their own programs.” — Mandy French, Chief Strategy Officer, CellFiber

Registration

The workshop is free to attend, with lunch and gifts provided. Seating is limited and attendance is by pre-registration only; selected participants will be notified in early July (no on-site registration available).

· Click here to register

· Date: Wednesday, 15 July 2026, 10:00-15:40

· Venue: Cytiva APAC Fast Trak™ Center — 2F, Building 2, BRC, 9 Songdomirae-ro, Yeonsu-gu, Incheon

About Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With   15,000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at its company website. Cytiva is proud to be part of Danaher. Visit  the company's website  to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health.

About CellFiber

CellFiber is a biotechnology company built on our proprietary cell encapsulation technology called “CellFiber®.” Our platform encapsulates living cells within hollow hydrogel microfibers, enabling closed, automated, and highly scalable 3D cell culture that supports the expansion of MSCs, iPSCs, and other cell types from research through GMP manufacturing. Guided by our vision, “Cell Culture Reimagined,” CellFiber is dedicated to advancing cell manufacturing technologies to make cell therapies more widely accessible and ultimately improve patients’ quality of life.